Case Summary: Sangamo Therapeutics Chapter 11
Sangamo Therapeutics filed for Chapter 11 after losing its major collaboration revenues and exhausting its liquidity, pursuing a court-supervised sale with stalking-horse bids from Lilly for its core platforms and Astellas for its Fabry program.